Wu Qingjian, Qi Lifeng, Li Hanxia, Mao Leilei, Yang Mingfeng, Xie Rongxia, Yang Xiaoyi, Wang Jian, Zhang Zongyong, Kong Jiming, Sun Baoliang
Department of Neurology, Shandong University School of Medicine, Jinan, Shandong, 250012, China.
Department of Neurology, Key Laboratory of Cerebral Microcirculation in Universities of Shandong, Affiliated Hospital of Taishan Medical University, Taian, Shandong, 271000, China.
Inflammation. 2017 Aug;40(4):1245-1253. doi: 10.1007/s10753-017-0567-8.
Roflumilast, a selective inhibitor for PDE4, is approved by FDA as an anti-inflammation drug for treatment of chronic obstructive pulmonary disease (COPD). This study investigates the effects of roflumilast on cerebral inflammation in the rat SAH model. Here, we show that subcutaneous administration of roflumilast (3 mg/kg) significantly improved the neurological deficits. Measurement of evans blue extravasation and brain water content revealed a significant reduction of blood-brain barrier permeability and brain edema. Importantly, roflumilast treatment remarkably decreased levels of IL-1β, IL-6, and TNF-α and the number of apoptotic neurons in the brain after SAH. These results indicate that roflumilast is effective in treating cerebral inflammation following SAH.
罗氟司特是一种磷酸二酯酶4（PDE4）的选择性抑制剂，已被美国食品药品监督管理局（FDA）批准作为一种抗炎药物用于治疗慢性阻塞性肺疾病（COPD）。本研究调查了罗氟司特对大鼠蛛网膜下腔出血（SAH）模型脑内炎症的影响。在此，我们发现皮下注射罗氟司特（3毫克/千克）可显著改善神经功能缺损。伊文思蓝外渗和脑含水量的测量结果显示血脑屏障通透性和脑水肿显著降低。重要的是，罗氟司特治疗显著降低了SAH后大脑中白细胞介素-1β（IL-1β）、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）的水平以及凋亡神经元的数量。这些结果表明罗氟司特对治疗SAH后的脑内炎症有效。
